NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 1 to 25 of 1360

Display Results as:

Medications Development for the Treatment of Alcohol Use Disorder - CT optional (U01) - RFA-AA-18-009

Organization: NIAAA 

Posting Date: 01-18-2018 

Expiration Date: 03-21-2018 

Activity Code: U01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds thorough the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will not support animal studies to prove efficacy of the candidate compound unless required by the Food and Drug Administration or peer review. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA. 

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional) - PA-18-569

Organization: NIDA 

Posting Date: 01-17-2018 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) encourages R01 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services. 

PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) - PA-18-574

Organization: NIH 

Posting Date: 01-16-2018 

Expiration Date: 04-06-2019 

Activity Code: R43/R44 

Summary: This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials. 

PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) - PA-18-575

Organization: NIH 

Posting Date: 01-16-2018 

Expiration Date: 04-06-2019 

Activity Code: R41/R42 

Summary: This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH. This Parent Funding Opportunity Announcement does not accept clinical trials. 

PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) - PA-18-576

Organization: NIH 

Posting Date: 01-16-2018 

Expiration Date: 04-06-2019 

Activity Code: R41/R42 

Summary: This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. 

PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) - PA-18-573

Organization: NIH 

Posting Date: 01-16-2018 

Expiration Date: 04-06-2019 

Activity Code: R43/R44 

Summary: This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) or Agency based on their scientific missions. 

Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01, Clinical Trials Not Allowed) - PAR-18-583

Organization: Roadmap 

Posting Date: 01-16-2018 

Expiration Date: 03-23-2018 

Activity Code: X01 

Summary: As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing are available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community. 

Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21 - Clinical Trial Not Allowed) - PAR-18-582

Organization: NIA 

Posting Date: 01-12-2018 

Expiration Date: 06-23-2020 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and ADRD. The R21 Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. 

Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 - Clinical Trial Optional) - PAR-18-581

Organization: NIA 

Posting Date: 01-12-2018 

Expiration Date: 06-09-2020 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and ADRD. This FOA invites Stage 0 (basic research) or Stage I (intervention development/modification) clinical trials, in line with the NIH Stage Model. 

Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R43/R44 Clinical Trial Optional) - PA-18-566

Organization: NIMH 

Posting Date: 01-12-2018 

Expiration Date: 01-06-2021 

Activity Code: R43/R44 

Summary: The overarching goal of the SBIR program at the National Institute of Mental Health (NIMH) is to support small businesses to develop technologies that can advance the mission of the Institute, including in basic neuroscience research relevant to mental disorders, translational and clinical research of mental disorders, clinical diagnosis or treatment of mental disorders, and dissemination of evidence-based mental health care. This FOA encourages SBIR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard SBIR guidelines. 

Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R41/R42) - PA-18-579

Organization: NIMH 

Posting Date: 01-12-2018 

Expiration Date: 01-06-2021 

Activity Code: R41/R42 

Summary: The overarching goal of the SBIR program at the National Institute of Mental Health (NIMH) is to support small businesses to develop technologies that can advance the mission of the Institute, including in basic neuroscience research relevant to mental disorders, translational and clinical research of mental disorders, clinical diagnosis or treatment of mental disorders, and dissemination of evidence-based mental health care. This FOA encourages SBIR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard SBIR guidelines. 

Patient Safety Learning Laboratories: Pursuing Safety in Diagnosis and Treatment at the Intersection of Design, Systems Engineering, and Health Services Research (R18) - RFA-HS-18-001

Organization: AHRQ 

Posting Date: 01-12-2018 

Expiration Date: 03-27-2018 

Activity Code: R18 

Summary: This R18 Request for Application (RFA) calls for the creation and utilization of Patient Safety Learning Laboratories. These learning laboratories are places and networks where transdisciplinary teams identify closely related threats to diagnostic or treatment efforts associated with a high burden of harm and cost. Following a systems engineering methodology, the learning laboratories stretch professional boundaries, envision innovative designs, and take advantage of brainstorming and rapid prototyping techniques that other leading industries employ. Promising prototypes undergo further develop-test-revise iterations, and subsequent integration as a working system. After further improvements are made to the integrated working system, its efficacy is evaluated in a realistic simulated or clinical setting. While applicants will select the area of diagnostic or treatment focus they consider of high significance, a flexible methodology -- problem analysis, design, development, implementation, and evaluation -- is required that parallels a systems engineering process to give an underlying structure to the work undertaken. In addition to longer-recognized patient safety issues, AHRQ also recognizes the importance of addressing harms caused by diagnostic failure. As a consequence, applications that address the diagnostic as well as the treatment sides of medicine are welcomed. 

New Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01 - Clinical Trials Not Allowed) - PAR-18-577

Organization: NHLBI 

Posting Date: 01-12-2018 

Expiration Date: 06-06-2020 

Activity Code: U01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications to establish new and innovative epidemiology cohort studies that will prospectively follow at least 2,000 participants and are designed to study a wide range of research hypotheses related to heart, lung, blood, and/or sleep phenotypes. Through this FOA, the National Heart, Lung, and Blood Institute (NHLBI) will support activities required to establish a new cohort, including identification and recruitment of cohort participants, detailed baseline data collection on all participants, biospecimen collection and storage, study infrastructure, and data quality control and analysis. 

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (UT2 -Clinical Trial Optional) - PAR-18-580

Organization: NIAAA 

Posting Date: 01-12-2018 

Expiration Date: 12-05-2020 

Activity Code: UT2 

Summary: This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA. An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required. 

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (U44 - Clinical Trial Optional) - PAR-18-578

Organization: NIAAA 

Posting Date: 01-12-2018 

Expiration Date: 12-05-2020 

Activity Code: U44 

Summary: This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA. An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required. 

African Association for Health Professions Education and Research (R25)(Clinical Trials Not Allowed) - RFA-TW-18-001

Organization: FIC 

Posting Date: 01-12-2018 

Expiration Date: 03-29-2018 

Activity Code: R25 

Summary: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this Fogarty International Center R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs by supporting the establishment of an African Association for Health Professions Education and Research (the "Association"). The Association will serve as a leadership and convening organization to network institutions across sub-Saharan Africa in order to jointly develop, disseminate, and share best practices, innovations, curricula, and policy and to engage in joint activities that will increase the quantity, quality and retention of African health professionals to address the crisis in HIV/AIDS and its' comorbidities on the continent. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on one or more of the following: Courses for Skills Development, Research Experiences, Mentoring Activities, Curriculum or Methods Development, and Outreach to broad communities and multiple stakeholders. 

Pediatric Device Consortia Grants Program (P50) - RFA-FD-18-004

Organization: FDA 

Posting Date: 01-12-2018 

Expiration Date: 03-08-2018 

Activity Code: P50 

Summary: The intended goal of this FOA is to facilitate the development, production, and distribution of pediatric medical devices. Although the FOA is issued by the FDA's Office of Orphan Products Development, the grant application is intended to encompass devices for all pediatric diseases and conditions, not just those that are rare. Applicants will request funding to serve as a nonprofit consortium to provide expert advising and support services to innovators of pediatric medical devices. The advising and services will focus on the total product life cycle for medical devices from concept, through pre-market development, to commercialization, and replacement by subsequent generation of devices. In addition, consortia should also provide expertise on evidence generation, including use of real world evidence, for pediatric device development. The pediatric population (i.e., neonates, infants, children, and adolescents) for medical devices is defined as individuals who are younger than 22 years of age (that is, from birth through the twenty-first year of life not including the twenty-second birthday) at the time of diagnosis or treatment. 

Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional) - PA-18-571

Organization: NIA 

Posting Date: 01-11-2018 

Expiration Date: 05-08-2021 

Activity Code: R03 

Summary: This Funding Opportunity Announcement (FOA) invites pilot/feasibility projects that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Pilot/feasibility research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. 

Underactive Bladder and Detrusor Activity in Aging (R01 Clinical Trial Optional) - PA-18-570

Organization: NIA 

Posting Date: 01-11-2018 

Expiration Date: 05-08-2021 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. 

Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional) - PA-18-572

Organization: NIA 

Posting Date: 01-11-2018 

Expiration Date: 05-08-2021 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. 

NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 - No Independent Clinical Trials) - PAR-18-436

Organization: NIDCD 

Posting Date: 01-09-2018 

Expiration Date: 01-08-2021 

Activity Code: K01 

Summary: The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. 

NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required) - PAR-18-435

Organization: NIDCD 

Posting Date: 01-09-2018 

Expiration Date: 01-08-2021 

Activity Code: K01 

Summary: The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development xperiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-18-436). 

NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U44 - Clinical Trials Optional) - PAR-18-563

Organization: NINDS 

Posting Date: 01-09-2018 

Expiration Date: 01-06-2021 

Activity Code: U44 

Summary: This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects. Successful applicants will collaborate and conduct the trial within the NIH StrokeNet. Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. 

NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01 - Clinical Trial Optional) - PAR-18-561

Organization: NINDS 

Posting Date: 01-09-2018 

Expiration Date: 11-06-2020 

Activity Code: U01 

Summary: This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. Successful applicants will collaborate and conduct the trial within the NIH StrokeNet. Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. NINDS intends that all multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet and that only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this program. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this FOA. 

International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional) - PA-18-568

Organization: NIDA 

Posting Date: 01-09-2018 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDA's international scientific priority areas (http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top